ProCE Banner Activity

Premium Education

CE

Opioid Use Disorder: Treatment and Recovery Options

Video

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: November 25, 2021

Expiration: November 25, 2021

No longer available for credit.

Course Fee

$30.00

Share

Additional Information

Program Medium

This program has been made available online.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities?
 

Activity Description

This is a ProCE Opioid Stewardship® education module and featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

This activity will highlight the ongoing struggles that are faced within the treatment of opioid use disorder (OUD), including stigma that prevents effective engagement in treatment, as well as the continued loss of life due to opioid-related overdoses. The activity will explore models of care used to treat OUD, that include harm reduction, psychosocial interventions, and pharmacotherapy. Newer and more innovative medication treatment options will also be discussed. Participants will be challenged to identify and promote evidence-based practices that best help patients navigate opioid use disorder recovery.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Discuss the rapidly changing climate with regard to opioid use (including illicit fentanyl and heroin) and overdose.
  • Elaborate on ways to reduce stigma surrounding opioid use disorder treatment, harm reduction, and recovery.
  • Review medication treatment options for opioid use disorder, including buprenorphine and naltrexone products.

Faculty

Kelly N. Gable, PharmD, BCPP
Professor, SIUE School of Pharmacy
Psychiatric Care Provider
Family Care Health Centers

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Gable has no relevant commercial or financial relationships to disclose.

CE Accreditation

Release Date: 11-25-2019
Expiration Date: 11-25-2022

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-513-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity. 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.